Costs associated with long-acting insulin analogues in patients with diabetes.

CONCLUSIONS: Despite higher drug costs, the real-world overall medical costs of LAIAs are not significantly different from those of NPH in patients with diabetes. The findings may be helpful for formulary decision making for patients with diabetes in a cost-constrained environment.
PMID: 30020738 [PubMed - in process]

Source: The American Journal of Managed Care - July 1, 2018 Category: Health Management Authors: Alemayehu B, Speiser J, Bloudek L, Sarnes E Tags: Am J Manag Care Source Type: research